TZD use was associated with improved A1c in aggregated lipodystrophy (least square mean reduction 2.2%) and in PPARG-related but not LMNA-related partial lipodystrophy (Level 4 evidence, Supplementary Data 3, Fig. 3). Here, PPARG is linked to partial lipodystrophy.